Loading organizations...
§ Private Profile · Emeryville, CA, USA
Slingshot Biosciences is a technology company.
Slingshot Biosciences has raised $49.0M across 2 funding rounds.
Key people at Slingshot Biosciences.
Slingshot Biosciences was founded in 2012 by Jeff Kim (Co-Founder).
Slingshot Biosciences has raised $49.0M in total across 2 funding rounds.
Slingshot Biosciences develops and manufactures high-performance synthetic cell mimics, offering standardized controls for precision flow cytometry and consistent results in cell-based assays. Its on-demand platform creates custom synthetic cell controls, tailored for specific biomarkers and assay requirements, directly addressing reproducibility and standardization needs in life science.
Jeff Kim founded Slingshot Biosciences over a decade ago, driven by the insight that biological sample variability severely limited progress in drug development, diagnostics, and cell therapies. His vision was to overcome these inconsistencies by creating stable, non-biological surrogates that mimic human cells, improving assay performance and data integrity.
The company’s synthetic cell controls serve researchers across academic and industrial sectors, including immunology, oncology, and gene therapy. Slingshot Biosciences empowers scientists and clinicians with robust tools, elevating analytical reliability and efficiency. Their long-term vision is to accelerate scientific discovery and therapeutic innovation through unparalleled precision in cell analysis.
Key people at Slingshot Biosciences.
Slingshot Biosciences was founded in 2012 by Jeff Kim (Co-Founder).
Slingshot Biosciences has raised $49.0M in total across 2 funding rounds.
Slingshot Biosciences's investors include ARCH Venture Partners, Northpond Ventures, Anterra Capital.
Slingshot Biosciences has raised $49.0M across 2 funding rounds. Most recently, it raised $26.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2023 | $26M Series A | ARCH Venture Partners, Northpond Ventures | Anterra Capital | Announced |
| Jul 1, 2021 | $23M Series A | Northpond Ventures | ARCH Venture Partners, Anterra Capital | Announced |
Slingshot Biosciences is a life sciences company founded in 2012 that develops precision-engineered synthetic cell mimics, known as TruCytes™, to serve as standardized reference controls for cell-based assays in diagnostics, therapeutics, and cell therapy manufacturing.[1][2][5] It targets labs, researchers, and manufacturers facing inconsistencies from biological cells by providing customizable, stable alternatives that reduce variability, cut costs, and enable on-demand scalability, addressing a critical gap in consistent reference materials for applications like flow cytometry, assay validation, and quality control.[2][5] The company shows strong growth momentum through recent product launches, such as TruCytes™ Potency CD20 & CD34 Stem Cell Gating Controls in October 2025 and partnerships like with Cellares for Cell Q™ platform integration to enhance cell therapy automation.[4][5]
Slingshot Biosciences was co-founded in 2012 by Jeff Kim, who serves as CEO and President, drawing from his background in material science, MEMS (micro-electro-mechanical systems), and bioorthogonal chemistry to tackle cell assay challenges from a first-principles approach.[2][4] The idea emerged from recognizing the need for reliable, repeatable controls amid limitations in biological materials; the team bootstrapped in the basement of Kim's Silicon Valley live-work condo, delivering their first large-scale batch of cell mimics just months after founding.[2] Early traction built on over a decade of stealth development, evolving from diagnostics to broader therapeutics, with headquarters now in Emeryville, CA.[2][4]
Slingshot rides the cell therapy and precision diagnostics boom, where manufacturing scale-up demands reliable QC amid regulatory pressures for consistency in adoptive therapies like CAR-T.[2][4] Timing aligns with 2025 advancements in automated platforms (e.g., Cellares Cell Q™), as market forces like rising cell therapy costs and assay variability hinder patient outcomes—Slingshot's mimics standardize readouts, enabling faster validation and commercialization.[2][4][5] It influences the ecosystem by shifting paradigms from fragile biologics to engineered synthetics, potentially accelerating pharma R&D and reducing failures in instrument calibration or therapy development.[1][2]
Slingshot is poised to expand into functional cell mimics for therapeutics, recapitulating engineered cell functions like payload delivery with on-demand printing, revolutionizing targeted therapies beyond diagnostics.[2] Trends like AI-driven personalization and cell therapy scalability will amplify its moat, built on 10+ years of proprietary tech, while partnerships signal commercial momentum.[2][4] Its influence may evolve into a gold-standard platform, making synthetic cells ubiquitous and transforming biotech workflows from lab to clinic—echoing its paradigm-shifting mission since that 2012 basement launch.[1][2]